-
Detailed Analysis Generate Full Report Add to Watchlist
Values as of: 2019-07-15
Values as of: 2019-07-15
The investment seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Dow Jones U.S. Health CareSM Index. The fund invests in securities and derivatives that ProShare Advisors believes, in combination, should have similar daily return characteristics as two times (2x) the daily return of the index. The index measures the performance of the healthcare sector of the U.S. equity market. Component companies include, among others, health care providers, biotechnology companies, medical supplies, advanced medical devices and pharmaceuticals. The fund is non-diversified.
Company Website : www.proshares.com
Currency: USD
Country : USA
Inception Date: 30/01/2007
Primary Benchmark: DJ US Health Care TR USD
Primary Index: S&P 500 TR USD
Gross Expense Ratio: 1.06%
Management Expense Ratio: 0.95 %
N/A
N/A
N/A
N/A
Symbol | Name | Mer | Price(Change) | Market Cap |
---|---|---|---|---|
SOJE | SOJE | 0.00 % |
+0.70 (+3.66%) |
USD 65.72B |
JEPI | JPMorgan Equity Premium Income.. | 0.00 % |
+0.44 (+0.79%) |
USD 32.43B |
DTB | DTB | 0.00 % |
+1.19 (+6.19%) |
USD 26.58B |
DFAC | Dimensional U.S. Core Equity 2.. | 0.00 % |
+0.36 (+1.19%) |
USD 26.00B |
GBTC | Grayscale Bitcoin Trust (BTC) | 0.00 % |
-0.05 (-0.08%) |
USD 23.75B |
JPST | JPMorgan Ultra-Short Income ET.. | 0.00 % |
+0.02 (+0.04%) |
USD 22.73B |
SGOV | iShares® 0-3 Month Treasury B.. | 0.00 % |
+0.01 (+0.01%) |
USD 19.79B |
AVUV | Avantis® U.S. Small Cap Value.. | 0.00 % |
+1.53 (+1.72%) |
USD 10.49B |
DFUV | Dimensional US Marketwide Valu.. | 0.00 % |
+0.37 (+0.94%) |
USD 10.15B |
DFAT | Dimensional U.S. Targeted Valu.. | 0.00 % |
+0.59 (+1.15%) |
USD 9.40B |
Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
---|---|---|---|---|---|
KGHG | 4.13 % | 0.00 % |
N/A |
N/A | |
EUSC | WisdomTree Europe Hedged .. | 2.32 % | 0.58 % |
+0.27 (+0.91%) |
USD 0.04B |
SMCX:SW | SPDR® MSCI Europe Small .. | 0.49 % | 0.00 % |
+2.60 (+0.91%) |
USD 0.22B |
IEUS | iShares MSCI Europe Small.. | 0.00 % | 0.40 % |
+0.87 (+0.91%) |
USD 0.12B |
SCZ | iShares MSCI EAFE Small-C.. | 0.00 % | 0.39 % |
+0.49 (+0.91%) |
USD 9.99B |
XXSC:LSE | db x-trackers MSCI Europe.. | 0.00 % | 0.00 % |
+46.50 (+0.91%) |
USD 1.10B |
MMS:PA | Lyxor Index Fund - Lyxor .. | 0.00 % | 0.00 % |
+5.33 (+0.91%) |
USD 0.27B |
SMC:PA | SPDR MSCI Europe Small Ca.. | 0.00 % | 0.00 % |
+3.70 (+0.91%) |
USD 0.22B |
LGWU:F | Lyxor Index Fund - Lyxor .. | 0.00 % | 0.00 % |
+2.70 (+0.91%) |
USD 0.29B |
ZPRX:F | SSgA SPDR ETFs Europe II .. | 0.00 % | 0.00 % |
+0.36 (+0.91%) |
USD 0.17B |
LGWU:XETRA | Amundi MSCI EMU Small Cap.. | 0.00 % | 0.00 % |
+3.90 (+0.91%) |
USD 0.27B |
ZPRX:XETRA | SPDR® MSCI Europe Small .. | 0.00 % | 0.00 % |
+0.37 (+0.91%) |
USD 0.17B |
1388:TSE | 0.00 % | 0.00 % |
N/A |
N/A |
Market Performance vs. Industry/Classification (Others) | Market Performance vs. Exchange (NYSE Arca) | ||||||
Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
YTD | |||||||
Capital Gain | 15.49% | 64% | D | 58% | F | ||
Dividend Return | 0.23% | 4% | F | 3% | F | ||
Total Return | 15.71% | 60% | D- | 54% | F | ||
Trailing 12 Months | |||||||
Capital Gain | 6.09% | 78% | C+ | 71% | C- | ||
Dividend Return | 0.39% | 6% | D- | 4% | F | ||
Total Return | 6.48% | 71% | C- | 63% | D | ||
Trailing 5 Years | |||||||
Capital Gain | 112.95% | 96% | N/A | 92% | A | ||
Dividend Return | 2.72% | 15% | F | 10% | F | ||
Total Return | 115.67% | 96% | N/A | 91% | A- | ||
Average Annual (5 Year Horizon) | |||||||
Capital Gain | 15.14% | 72% | C | 73% | C | ||
Dividend Return | 15.50% | 67% | D+ | 71% | C- | ||
Total Return | 0.37% | 39% | F | 10% | F | ||
Risk Return Profile | |||||||
Volatility (Standard Deviation) | 20.01% | 76% | C+ | 63% | D | ||
Risk Adjusted Return | 77.49% | 87% | B+ | 87% | B+ | ||
Market Capitalization | 0.07B | 51% | F | 24% | F |
Target Price Action | Rating Action | Analyst | Rating | Price | Date |
---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
The company had positive total cash flow in the most recent four quarters.
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
The company has under performed its peers on annual average total returns in the past 5 years.